Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …

Importance Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of
patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis …

Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …

Systemic immunoglobulin light-chain amyloidosis is characterized by pathologic deposition
of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment …

The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …

Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of
cardiomyopathy are common presenting features, and patients often are referred to …

PURPOSE Binary cardiac response assessment using cardiac biomarkers is prognostic in
light chain amyloidosis. Previous studies suggested four-level cardiac responses using N …

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the
accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an …

Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder leading to
progressive and life-threatening organ failure. The heart and the kidneys are the most …

The term amyloidosis refers to a group of disorders in which protein fibrils accumulate in
certain organs, disrupt their tissue architecture, and impair the function of the effected organ …